American Journal of Infectious Diseases and Microbiology
ISSN (Print): 2328-4056 ISSN (Online): 2328-4064 Website: Editor-in-chief: Maysaa El Sayed Zaki
Open Access
Journal Browser
American Journal of Infectious Diseases and Microbiology. 2015, 3(3), 104-111
DOI: 10.12691/ajidm-3-3-3
Open AccessArticle

The Challenge to Interpret Antimicrobial Susceptibility at a Small Community Hospital

Patricia Sealy1, and William H. Swanston2

1School of Pharmacy, Faculty of Medical Sciences, The University of the West Indies, Eric Williams Medical Sciences Complex, Champs Fleurs, Trinidad and Tobago

2Consultant Microbiologist, Sangre Hospital, Eastern Regional Health Authority, Trinidad and Tobago

Pub. Date: May 15, 2015

Cite this paper:
Patricia Sealy and William H. Swanston. The Challenge to Interpret Antimicrobial Susceptibility at a Small Community Hospital. American Journal of Infectious Diseases and Microbiology. 2015; 3(3):104-111. doi: 10.12691/ajidm-3-3-3


Objective: We aimed to determine the prevailing resistance rates at a local community hospital for a select group of gram-positive and gram-negative microorganisms for the period 2008-2012. Methods: Aerobic and facultative anaerobic culture isolates representing blood, urine and wounds specimens from all wards were tested at the Microbiology Laboratory, using the MicroScan AutoScan4, to determine antimicrobial susceptibility at the local community hospital. Results: the findings allude to the prevalence of resistance at the institution for the period under review. Conclusion: Resistance trends are speculative at best without the inclusion of molecular characterization of resistance and consumption data. Pharmacists should play a greater role in the determination of resistance by providing the microbiologist with consumption or utilization data, such as the daily defined dose. The inclusion of the daily defined dose in the estimation of resistance would allow clinicians to determine if selective pressure may have contributed to the prevailing resistance rates.

Antimicrobial resistance Antimicrobial susceptibility Antimicrobial stewardship Antibiogram gram positive organisms gram negative organisms antimicrobial agents

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  T.G.Emori, D.H. Culver, T.C. Horan, W.R. Jarvis, J.W. White, D.R. Olson, S. Banerjee, J.R. Edwards, W.J.Martone, R.P.Gaynes, et al. “National nosocomial infections surveillance system (NNIS): description of surveillance methods”, Am J Infect Control, 1991 Feb; vol. 19, no. 1, pp. 19-35, Feb. 1991.
[2]  W. R. Jarvis, “Benchmarking for prevention: the Centers for Disease Control and Prevention's National Nosocomial Infections Surveillance (NNIS) system experience”, Infection, vol. 31 no. 2, pp. 44-8, Dec. 2003.
[3]  G. E. Stein, “Antimicrobial resistance in the hospital setting: impact, trends, and infection control measures”, Pharmacotherapy, vol. 25, no. 10 Pt 2, pp.44S-54S. Oct. 2005.
[4]  R. N. Jones, “The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance”, DiagnMicrobiol Infect Dis., vol. 25, no. 4, pp. 153-61, Aug. 1996.
[5]  D.F. Sahm, M.K. Marsilio, G. Piazza, “Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database--USA”. Clin Infect Dis., vol. 29, no. 2, pp. 259-63, Aug. 1999.
[6]  H. Hanberger, D.Diekema, A.Fluit, R. Jones, M.Struelens,R. Spencer, M. Wolff, “Surveillance of antibiotic resistance in European ICUs”, J Hosp Infect., vol. 48, no. 3, pp. 161-76. Jul. 2001.
[7]  G.G. Zhanel, M. DeCorby, N. Laing, B. Weshnoweski, R. Vashisht, F. Tailor, K.A. Nichol, A. Wierzbowski, P.J. Baudry, J.A. Karlowsky, P. Lagacé-Wiens, A. Walkty, M. McCracken, M.R. Mulvey, J. Johnson, Canadian Antimicrobial Resistance Alliance (CARA), D.J. Hoban, “Antimicrobial-resistantpathogens in intensive care units in Canada: results of the CanadianNationalIntensive Care Unit (CAN-ICU) study, 2005-2006.” Antimicrob Agents Chemother, vol. 52, no. 4, pp. 1430-7. doi: 10.1128/AAC.01538-07, Epub Feb. 2008, Apr. 2008.
[8]  H.J. van Loon, M.R.Vriens, A.C.Fluit, A.Troelstra, C. van der Werken, J.Verhoef, M.J.Bonten. “Antibiotic rotation and development of gram-negative antibiotic resistance”, Am J RespirCrit Care Med., vol. 171, no. 5, pp. 480-7. EpubOct. 2004, Mar. 2005.
[9]  L.R.Merz, D.K. Warren, M.H.Kollef, S.K.Fridkin, V.J. Fraser. “The impact of an antibiotic cycling program on empirical therapy for gram-negative infections”, Chest, vol. 130, no. 6, pp. 1672-8. Dec. 2006.
[10]  K.M. Bennett, J.E. Scarborough, M. Sharpe, E.Dodds-Ashley, K.S. Kaye, T.Z. Hayward 3rd, S.N. Vaslef, “Implementation of antibiotic rotation protocol improves antibiotic susceptibility profile in a surgical intensive care unit”, J Trauma. vol. 63, no. 2, pp. 307-11. Aug. 2007.
[11]  Lund,M.E. and R.W. Hawkinson, "Evaluation of the Prompt InoculationSystem for Preparation of Standardized BacterialInocula." J.Clin.Microbiol vol.18. no 1, pp.84-91 July 1983.
[12]  Clinical Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. CLSI document M100-S22. Wayne, PA2012
[13]  G. Cornaglia, W. Hryniewicz, V. Jarlier, G. Kahlmeter, H. Mittermayer, L Stratchounski, F. Baquero, ESCMID Study Group for Antimicrobial Resistance Surveillance, “European recommendations for antimicrobial resistance surveillance”, ClinMicrobiol Infect. vol. 10, no. 4, pp. 349-83, Apr. 2004.
[14]  J. G. Gums, B. J. Epstein, “Fluoroquinolone- and Methicillin-Resistant Staphylococcus Aureus: Insights from the Antimicrobial Resistance Management Program”, Journal of Pharmacy Technology, vol. 21, no. 3, pp. 123-128.
[15]  J.W. Warren, E.Abrutyn, J.R.Hebel, J.R. Johnson, A.J. Schaeffer, W.E.Stamm, “Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA)”, Clin Infect Dis., vol. 29, no. 4, pp. 745-58, Oct. 1999.
[16]  F. Perez, A.Endimiani, K.M.Hujer, R.A.Bonomo, “The continuing challenge of ESBLs”, CurrOpinPharmacol, vol. 7, no. 5, pp. 459-69. EpubSept. 2007, Sep 17, Oct. 2007.
[17]  S. Sharp, K. Bennett, and A. Coover. “ CLSI modified cephalosporin 1 breakpoints will not detect all ESBL-producing Enterobacteriaceae as compared to currently recommended CLSI confirmatory testing”, 49th 3 Interscience Conference on Antimicrob. Agents Chemother. San Francisco; 2009. D-734.
[18]  E. S. Moland, J. A. Black, N. D. Hanson and K. S. Thomson. Concerns about ESBL testing in 2010. 49th 6 Interscience Conference on Antimicrob. Agents Chemother. San Francisco; 2009. D-728.
[19]  P. Wang, F. Hu, Z.Xiong, X. Ye, D. Zhu, Y.F. Wang, M. Wang, “Susceptibility of extended-spectrum-beta-lactamase-producing Enterobacteriaceae according to the new CLSI breakpoints”, J ClinMicrobiol, vol. 49, no. 9, pp. 3127-31.
[20]  M. Souli, I.Galani, H.Giamarellou, “Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe”, Euro Surveill, vol. 13, no. 47, pii 19045. Nov. 2008.
[21]  T.A. Davies, A. M.Queenan, B.J. Morrow, W. Shang, K.Amsler, W. He, A.S. Lynch, C. Pillar, R.K.Flamm, “Longitudinal survey of carbapenem resistance and resistance mechanisms in Enterobacteriaceae and non-fermenters from the USA in 2007-09”, J AntimicrobChemother., vol. 66, no. 10, pp. 2298-307.
[22]  M.J.Schwaber, S.Navon-Venezia, D. Schwartz, Y.Carmeli, “High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae”, Antimicrob Agents Chemother, vol. 49, no. 5, pp. 2137-9, May 2005.
[23]  R. Colodner, Z.Samra, N. Keller, H.Sprecher, C. Block, N.Peled, T.Lazarovitch, R.Bardenstein, O. Schwartz-Harari, Y. Carmeli, Israel ESBL Group, “First national surveillance of susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel”, DiagnMicrobiol Infect Dis., vol. 57, no. 2, pp. 201-5, Feb. 2007.
[24]  T.K. McKinney, V.K. Sharma, W.A. Craig, G.L. Archer, “Transcription of the gene mediating methicillin resistance in Staphylococcus aureus (mecA) is corepressed but not coinduced by cognate mecA and beta-lactamase regulators”, J Bacteriol., vol. 183, no. 23, pp. 6862-8, Dec. 2001.
[25]  T.R. Walsh, R.A. Howe, “The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus”, Annu Rev Microbiol., vol. 56, no. pp. 657-75. EpubJan. 2002, Jan, 2002.
[26]  F.Goldstein, “The potential clinical impact of low-level antibiotic resistance in Staphylococcus aureus”, J AntimicrobChemother., vol. 59, no. 1, pp. 1-4. EpubOct. 2006, Jan. 207.
[27]  Centers for Disease Control and Prevention (CDC). Laboratory detection of vancomycin-intermediate/resistant Staphylococcus aureus (VISA/VRSA). Atlanta; 2006.
[28]  Centers for Disease Control and Prevention. Healthcare-associated Infections (HAIs): CDC Reminds Clinical Laboratories and Healthcare Infection Preventionists of their Role in the Search and Containment of Vancomycin-Resistant Staphylococcus aureus (VRSA). Available: [Accessed: 29-Aug-2011].
[29]  G.K.Siberry, T.Tekle, K. Carroll, J. Dick, “Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro”, Clin Infect Dis., vol. 37, no. 9, pp. 1257-60. Epub 2003 Oct, Nov. 2003.
[30]  D.Drinkovic, E.R. Fuller, K.P. Shore, D.J. Holland, R. Ellis-Pegler. “Clindamycin treatment of Staphylococcus aureus expressing inducible clindamycin resistance”, J AntimicrobChemother., vol. 48, no. 2, pp. 315-6, Aug. 2001.
[31]  Standards Institute. Performance standards for antimicrobial susceptibility testing; 19th informational supplement. Approved standard M100-S19. Wayne, PA: Clinical and Laboratory Standards Institute, 2009.
[32]  J.M. Swenson, N.C. Clark, M.J. Ferraro, D.F.Sahm, G.Doern, M.A.Pfaller, L.B.Reller, M.P. Weinstein, R.J.Zabransky, F.C.Tenover, “Development of a standardized screening method for detection of vancomycin-resistant enterococci”, J ClinMicrobiol., vol. 32, no. 7, pp. 1700-4, Jul. 1994.
[33]  M.V. O'Sullivan, Y.Cai, F. Kong, X. Zeng, G.L. Gilbert, “Influence of disk separation distance on accuracy of the disk approximation test for detection of inducible clindamycin resistance in Staphylococcus spp.”, J ClinMicrobiol., vol. 44, no. 11, pp. 4072-6. Epub Sept. 2006, Nov. 2006.
[34]  Centers for Disease Control and Prevention. Vancomycin-resistant Enterococci (VRE) and the Clinical Laboratory. Atlanta; 2010. [Accessed: 29-Aug-2011].